HC Wainwright Reiterates “Neutral” Rating for Aardvark Therapeutics (NASDAQ:AARD)

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “neutral” rating reissued by HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s price target would indicate a potential downside of 1.32% from the company’s previous close. HC Wainwright also issued estimates for Aardvark Therapeutics’ FY2027 earnings at ($1.98) EPS.

Several other equities analysts have also recently issued reports on AARD. B. Riley Financial reduced their target price on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Morgan Stanley restated an “underweight” rating and set a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. BTIG Research lowered Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Aardvark Therapeutics presently has an average rating of “Hold” and an average target price of $16.30.

Aardvark Therapeutics Price Performance

NASDAQ AARD opened at $6.08 on Monday. The stock has a market capitalization of $133.03 million, a PE ratio of -1.89 and a beta of 3.93. Aardvark Therapeutics has a 1 year low of $3.35 and a 1 year high of $17.94. The business’s 50-day moving average is $4.82 and its 200 day moving average is $7.42.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that Aardvark Therapeutics will post -3.46 earnings per share for the current year.

Institutional Trading of Aardvark Therapeutics

Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new position in shares of Aardvark Therapeutics during the 1st quarter worth approximately $267,000. Bank of New York Mellon Corp lifted its stake in shares of Aardvark Therapeutics by 30.8% in the 1st quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock valued at $111,000 after purchasing an additional 6,905 shares during the period. XTX Topco Ltd purchased a new position in shares of Aardvark Therapeutics in the 4th quarter valued at approximately $335,000. Superstring Capital Management LP bought a new stake in shares of Aardvark Therapeutics during the fourth quarter valued at approximately $912,000. Finally, Millennium Management LLC boosted its position in shares of Aardvark Therapeutics by 51.2% during the fourth quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock valued at $6,344,000 after purchasing an additional 163,717 shares in the last quarter.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.